This move is archived. Current quotes and coverage live on the stock page.
Follow VRTX
Vertex Pharmaceuticals is seeing a rise in its stock price after positive results from clinical trials.
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) shares are up 1.79%, closing at CA$525.60. This increase follows encouraging developments in its kidney disease treatment pipeline, especially the recent positive data from its Phase IIb AMPLIFIED study.
Vertex Pharmaceuticals Inc
VRTX.US
VRTX.US
Vertex Pharmaceuticals Inc
WealthAwesomeMarket cap
$141.65B
P/E
32.5x
52W high
$568.67
52W low
$406.67
1W change
+6.89%
Beta
0.28
Analyst Price Targets
Based on 32 analysts covering VRTX · as of Nov 2, 2026
Wall Street analysts forecast VRTX stock price to rise 3.3% over the next 12 months.
Consensus
Buy4.34 / 5.00
Avg. Target
C$571.46
+3.3% Upside
Current Price
C$553.15
Last close
Analyst Breakdown (32 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on VRTX's historical volatility
30-Day Vol
27.6%
Annualized
90-Day Vol
28.9%
Annualized
Trend (90d)
+45.7%
Annualized drift
90d Mean
C$651.32
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$584.11 | C$531.00 – C$642.53 |
| 60 trading days | C$616.80 | C$539.00 – C$705.82 |
| 90 trading days | C$651.32 | C$552.18 – C$768.25 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors are reacting positively to Vertex's progress in its drug pipeline, particularly for kidney disease, which could lead to significant cash flows in the future.
184.7% Share Price Gain Over Five Years
Vertex Pharmaceuticals has achieved an impressive 184.7% increase in share price over the past five years, showcasing its strong market performance.
Bull case
Vertex's diverse pipeline, which includes treatments for kidney disease and pain management, positions the company well for future growth. Some analysts believe it could be undervalued by as much as 8%.
Bear case
However, there are concerns that the current stock price might be overvalued by 20%. This assumes that the company executes its pipeline flawlessly and successfully diversifies beyond cystic fibrosis.
Positive Clinical Trial Results Boost Investor Confidence
Vertex recently shared positive results from its Phase IIb AMPLIFIED study, which tested its investigational drug inaxaplin for treating APOL1-mediated kidney disease. The results showed significant reductions in urine protein levels, suggesting the drug's potential effectiveness. This news has helped drive the stock's upward momentum as investors look forward to more advancements in Vertex's treatment options.
Market Valuation and Future Prospects
Despite the recent gains, analysts have mixed opinions on Vertex's market valuation. The company's current P/E ratio is 30.04, raising questions about whether the stock price truly reflects its future cash generation potential. With a growing pipeline and recent acquisitions, including Crinetics, Vertex is set for future growth. Still, some analysts warn that the stock may be overvalued based on current projections.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
